Teva Pharmaceuticals Stock: An In-Depth Analysis for Serious Investors
Teva Pharmaceuticals stock (NYSE: TEVA) is the world's largest generic drug manufacturer by volume, and that scale is both its core asset and its core problem. The company ships roughly 120 billion generic pills annually, generating $15.8 billion in revenue in fiscal year 2025, yet a $16.8 billion net debt position from the 2016 Allergan Generics acquisition still shapes every investment decision. The teva pharmaceuticals stock trades around $15 to $18 per share as of April 2026, putting its enterprise value near $26 billion. Understanding whether that price reflects fair value or a value trap requires dissecting three things: the debt trajectory, the AUSTEDO branded pipeline, and competitive dynamics in generic drug pricing.
This post gives you the full picture without shortcuts.
Key Takeaways
- Teva carries approximately $16.8 billion in net debt, down from a peak of $34 billion in 2017, targeting sub-$15 billion by end of 2026.
- AUSTEDO (deutetrabenazine) reached $1.4 billion in annual revenue in 2025, growing 28% year-over-year, and is the clearest path to re-rating.
- The forward P/E on TEVA sits near 6.1x on consensus 2026 earnings of approximately $2.40 per share.
- Generic drug pricing erosion runs 5 to 8% annually in the U.S. market, forcing Teva to launch hundreds of new products just to hold revenue flat.
- The opioid settlement framework has removed most legal tail risk, with structured payments through 2035 spread across state agreements.
- At EV/EBITDA near 7.2x, TEVA screens at a discount to pharma peers, but that discount requires sustained EBITDA delivery to close.
What Teva Actually Does
Teva operates two segments: Generics and Innovative Medicines.
The Generics segment (roughly 60% of revenue) produces off-patent drugs at scale, competing on cost, speed to market, and regulatory speed. It holds the number-one or number-two position in the U.S., Europe, and several emerging markets. Volume is the business model. Margins are thin. The U.S. generics market has seen relentless price compression since 2016 as consolidated pharmacy benefit managers pushed suppliers into annual price reductions.
Innovative Medicines (roughly 40% of revenue) centers on three branded products:
- AUSTEDO (deutetrabenazine) for tardive dyskinesia and Huntington's chorea. $1.4 billion in 2025 revenue with patent protection through the early 2030s.
- AJOVY (fremanezumab) for migraine prevention. Roughly $370 million annually, competing in a crowded CGRP class against Amgen's Aimovig and Eli Lilly's Emgality.
- COPAXONE (glatiramer acetate) for multiple sclerosis. Legacy product in structural decline as biosimilar competition compresses share and price. Revenue fell below $450 million in 2025.
The mix shift from declining COPAXONE to growing AUSTEDO is the central thesis. If AUSTEDO hits $2 billion by 2028, free cash flow could reach $3.5 to $4 billion annually, enough to retire meaningful debt and support a re-rating.
The Debt Story: Where Teva Stands in 2026
The $40.5 billion Allergan deal in 2016 nearly broke the company. Teva's management since 2017 has reduced that debt load through asset sales, cost cuts, and steady free cash flow.
| Year | Net Debt ($ bn) | Net Debt / EBITDA |
|---|---|---|
| 2017 | 34.1 | 7.8x |
| 2019 | 26.4 | 5.1x |
| 2021 | 21.7 | 4.3x |
| 2023 | 18.4 | 3.9x |
| 2025 | 16.8 | 3.5x |
| 2026E | ~15.0 | ~3.1x |
The direction is right. The pace is slow. At the current rate of $1.5 to $2 billion in annual debt reduction, Teva reaches investment-grade debt ratios (2.5x or below) around 2028 to 2029. That timeline matters because investment-grade status opens the door to cheaper refinancing and potentially a dividend reinstatement, both of which historically trigger institutional re-pricing.
The current credit spread on Teva's longer-dated bonds implies a yield around 7.4%, well above pharmaceutical investment-grade peers at 4.5 to 5.0%. Close that spread and the equity re-rates.
Teva Pharmaceuticals Stock Valuation: Cheap or Value Trap?
Running teva pharmaceuticals stock through our screener on metrics that matter for a debt-heavy pharmaceutical name:
| Metric | TEVA | Pharma Sector Median |
|---|---|---|
| Forward P/E | 6.1x | 14.2x |
| EV/EBITDA | 7.2x | 11.8x |
| EV/Revenue | 1.7x | 3.4x |
| Price/Free Cash Flow | 8.4x | 16.3x |
| Net Debt/EBITDA | 3.5x | 1.2x |
| ROIC | 7.8% | 13.4% |
The discount is real. A 6.1x forward P/E is a number you see on distressed industrials, not on a company with a branded $1.4 billion product growing 28%. The market prices in three risks simultaneously: continued generic pricing erosion, execution on AUSTEDO guidance, and residual legal exposure from opioid-adjacent claims.
The value case: if Teva delivers $2.4 billion in 2026 EPS and de-levers to 3.1x EBITDA, a re-rating to 10x forward earnings produces a stock near $24, roughly 40% above the April 2026 price. The risk case is equally clear: if generic pricing accelerates its decline and AUSTEDO misses, free cash flow compresses, debt reduction stalls, and the discount is justified.
AUSTEDO: The Decisive Variable
AUSTEDO is the only Teva asset that can meaningfully move the investment needle over the next three years. Tardive dyskinesia affects roughly 500,000 diagnosed patients in the U.S. alone, and fewer than 25% are currently treated. That penetration gap is the growth runway.
Key AUSTEDO data points for 2026:
- Net revenue guidance: $1.6 to $1.7 billion for 2026.
- Gross margin above 90%, meaning each dollar of revenue flows almost entirely to operating income.
- Patent cliff not until the early 2030s, giving the asset a long exclusivity window.
- Huntington's chorea indication provides a second, smaller but durable revenue stream.
Competition risk is limited. Neurocrine's Ingrezza (valbenazine) is the primary alternative, but AUSTEDO has differentiated on dosing convenience and formulary placement in several major payer contracts.
Generic Drug Pricing: The Structural Headwind
Generic drug pricing in the U.S. has fallen roughly 6% annually for the past seven years. Teva's U.S. generics business, which generates about $5 billion in revenue, loses $300 million in annual revenue from pricing alone before new launches are added. The company must launch 200 to 300 new generic products per year simply to offset that erosion.
In Europe, governments set prices centrally. Pricing is lower in absolute terms but more stable. Teva's European generics business generates steadier margins than its U.S. counterpart.
Biosimilars represent the next wave. Teva launched biosimilar versions of AbbVie's Humira and has several oncology biosimilars in development. Biosimilar gross margins run 40 to 55%, roughly double U.S. small-molecule generics, making this segment mix-improving if Teva captures meaningful share.
What the VMCI Score Tells You About TEVA
The ValueMarkers Composite Integrity Score weights five pillars: Value (35%), Quality (30%), Integrity (15%), Growth (12%), and Risk (8%).
On Value, TEVA scores strongly. Forward P/E of 6.1x and EV/EBITDA of 7.2x are at the low end of the pharmaceutical sector.
On Quality, the score is middling. ROIC of 7.8% falls below the threshold we consider quality (above 12%). Gross margins are high in branded but diluted by generics.
On Integrity, the opioid settlement removes the most egregious historical mark, but accounting complexity across multiple restructuring charges warrants scrutiny of adjusted versus GAAP earnings.
On Growth, AUSTEDO provides a clear growth driver, but consolidated revenue growth is modest at 3 to 5% given generics headwinds.
On Risk, the debt load at 3.5x EBITDA and the $16.8 billion in net debt keep the risk score suppressed.
TEVA is a high-Value, moderate-Quality, moderate-Risk situation. It belongs in a portfolio only if you have conviction on the debt trajectory and AUSTEDO execution.
Five Checks Before You Buy Teva Pharmaceuticals Stock
Before committing capital, run these five checks:
- Quarterly AUSTEDO revenue versus guidance. Any miss below $1.6 billion for 2026 changes the thesis materially.
- U.S. generic pricing trends. Track the IQVIA generic price index quarterly. Acceleration below negative 8% per year tightens cash flow.
- Debt repayment schedule. Teva's 2026 maturities total roughly $2.1 billion. Confirm refinancing terms and cost of new debt.
- Opioid payment cash flows. Annual payments under the settlement framework run $500 to $700 million through 2035. Model these as hard commitments.
- Free cash flow conversion. Target free cash flow of $1.8 to $2.2 billion for 2026. Any shortfall signals earnings quality issues or working capital deterioration.
You can run all five checks in parallel using the data fields in our screener.
Further reading: SEC EDGAR · FRED Economic Data
Why TEVA stock analysis Matters
This section anchors the discussion on TEVA stock analysis. The detailed treatment, formula, and worked examples appear in the body of this article above. The points below summarize the most important takeaways for value investors who want to apply TEVA stock analysis in real portfolio decisions. ValueMarkers exposes the underlying data on every covered ticker via the screener and stock profile pages, so the concepts in this article translate directly into actionable filters.
Key inputs for TEVA stock analysis
See the main discussion of TEVA stock analysis in the sections above for the full treatment, including the inputs, the calculation methodology, the typical sector benchmarks, and the most common pitfalls to avoid. The ValueMarkers screener lets value investors filter the full universe of 100,000+ stocks across 73 exchanges using TEVA stock analysis alongside the rest of the 120-indicator composite, with sector percentiles and historical trends shown on every stock profile.
Sector benchmarks for TEVA stock analysis
See the main discussion of TEVA stock analysis in the sections above for the full treatment, including the inputs, the calculation methodology, the typical sector benchmarks, and the most common pitfalls to avoid. The ValueMarkers screener lets value investors filter the full universe of 100,000+ stocks across 73 exchanges using TEVA stock analysis alongside the rest of the 120-indicator composite, with sector percentiles and historical trends shown on every stock profile.
Related ValueMarkers Resources
- Forward Pe — Glossary entry for Forward Pe
- Enterprise Value to EBITDA (EV/EBITDA) — Enterprise Value to EBITDA is the metric used to how cheaply a stock trades relative to its fundamentals
- Pe Ratio — Glossary entry for Pe Ratio
- Gold Mining Etf — related ValueMarkers analysis
- Mp Materials Stock Valuation — related ValueMarkers analysis
- Walmart Stock Valuation Is Wmt Worth The Premium Price — related ValueMarkers analysis
Frequently Asked Questions
what happens if the stock market crashes
A stock market crash would pressure teva pharmaceuticals stock in the short term, since debt-heavy companies face higher perceived default risk when credit markets tighten. However, generic pharmaceuticals are defensive in a recession because people do not stop taking medication. Teva's revenue held up during the 2020 COVID selloff, declining less than 5% while the S&P 500 fell 34% peak-to-trough.
what time does the stock market open
U.S. stock markets, including the NYSE where TEVA is listed, open at 9:30 a.m. Eastern Time on weekdays excluding federal holidays. Pre-market trading in TEVA begins at 4:00 a.m. Eastern through most major brokerages, though liquidity is thinner and spreads are wider than during regular session hours.
are stock markets closed today
U.S. stock markets follow the NYSE holiday calendar, which includes nine federal holidays annually: New Year's Day, Martin Luther King Jr. Day, Presidents' Day, Good Friday, Memorial Day, Juneteenth, Independence Day, Labor Day, Thanksgiving, and Christmas. Check the NYSE official calendar for exact closure dates in any given year.
what time does the stock market close
The NYSE closes at 4:00 p.m. Eastern Time on regular trading days. After-hours trading in TEVA runs from 4:00 p.m. to 8:00 p.m. Eastern through most brokerages. Earnings releases for Teva typically come out pre-market or after-hours to avoid disrupting the regular session.
when does the stock market open
The NYSE opens at 9:30 a.m. Eastern Time. For Teva investors, the first 30 minutes of trading are often most volatile following earnings releases or FDA news on a branded drug approval or rejection. Limit orders placed before the open help manage execution risk during that period.
why is the stock market down today
The stock market falls on any given day for dozens of reasons: interest rate expectations shifting, disappointing macro data, earnings misses from index heavyweights, or geopolitical news. For teva pharmaceuticals stock specifically, watch for FDA decisions on competing products, quarterly earnings surprises, and credit market moves that affect the cost of refinancing its debt.
Use our screener to track Teva's AUSTEDO revenue, debt-to-EBITDA, and forward P/E alongside 120+ other indicators updated quarterly.
Written by Javier Sanz, Founder of ValueMarkers. Last updated April 2026.
Ready to find your next value investment?
ValueMarkers tracks 120+ fundamental indicators across 100,000+ stocks on 73 global exchanges. Run the methodology above in seconds with our stock screener, or see today's top-ranked names on the leaderboard.
Related tools: DCF Calculator · Methodology · Compare ValueMarkers
Disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making investment decisions.